SlideShare a Scribd company logo
Patients’ voice in access decisions
A discussion of the roles patients can play
Nick Meade
Director of Policy
Genetic Alliance UK
Genetic Alliance UK is the national charity working to improve
the lives of patients and families affected by all types of
genetic conditions. We are an alliance of over 180 patient
organisations.
Our aim is to ensure that high quality services, information and
support are provided to all who need them. We actively
support research and innovation across the field of genetic
medicine.
Who are we?
• Patient voice as information providers
• Patient voice in decision making
• Patient voice in policy development
• Patient voice as an individual
Patients’ voice in access decisions
A discussion of the roles patients can play
“Health technology assessment is the systematic evaluation
of the properties and effects of a health technology,
addressing the direct and intended effects of this
technology, as well as its indirect and unintended
consequences, and aimed mainly at informing decision
making regarding health technologies.”
World Health Organisation
Raw material: information
Patient voice type 1
Information providers
Some types of information required by HTA bodies:
•Population size? How many people are affected? How many people need / want
the intervention?
•What is the impact of the condition? Burden of illness?
•How does the disease progress? At what stage should the treatment be given?
•What are the adverse events associated with the treatment? What is their impact?
•How will the treatment be delivered within the health service?
•How effective is the medicine? Is it uniformly effective? Does it work better in
certain circumstances?
•How much does it cost? What is the value of the improvements it makes?
Are these questions valid? Can we answer them in the case of the treatment under
discussion?
Patient voice type 1
Information providers
Example from:
The Society for Mucopolysaccharide Diseases (the MPS Society) is the only UK
charity supporting individuals and families affected by MPS, Fabry and related
diseases.
Response to scoping for NICE’s Highly Specialised Technology evaluation of
Elosulfase alfa for treating mucopolysaccharidosis type 4A
Patient voice type 1
Information providers
What is the population size?
NICE’s DRAFT Scope for Elosulfase alfa for treating mucopolysaccharidosis type 4A
“The exact prevalence of mucopolysaccharidosis type IVA is not known. It has been
estimated to affect approximately 1 in 250,000 people in the UK, with 1 new
diagnosis per 220,000 live births. This equates to about 200 people living with
mucopolysaccharidosis type IVA, and approximately 3 new diagnoses per year, in
England.”
MPS Society’s response:
“The MPS Society has had an MPSIVA registry since 1984 and has collaborated
with clinical sites to ensure accuracy and completeness. 94 people living with a
biochemical diagnosis in England are on the MPSIVA registry and we do not
believe any are missing.”
Patient voice type 1
Information providers
What outcomes should be considered?
NICE’s DRAFT Scope for Elosulfase alfa for treating mucopolysaccharidosis type 4A
“The outcome measures to be considered include:
MPS Society’s response:
“Please consider:
But is it easy for patients to play this vital role?
Patient voice type 1
Information providers
• mobility
• respiratory and cardiac function
• growth and development
• vision and hearing
• sleep apnoea
• mortality
• adverse effects of treatment
• health-related quality of life (for patients
and carers).”
• fatigue
• pain
• endurance.”
Patients are a key stakeholder in healthcare. They should play a role in decision
making.
Patients and patient groups understand the potential beneficiaries point of view
• Is the patient submission being considered appropriately?
• Are all potential benefits from this medicine being valued equally?
• Just how valuable is a shift from daily treatments to weekly?
Patient participation in marketing authorisation decision making has changed the
culture of EMA scientific committees.
• At least one trained disinterested patient should be part of the decision making
panel.
Patient voice type 2
Decision maker
NICE’s HST Evaluation Committee has:
3 lay members (including someone with knowledge / experience of
ethical issues)
• Professional ethicist
• Member of public
• Patient representative (conflicted for one of the products!)
Scottish Medicines Consortium
2 public partners
• One of whom has been public partner for Healthcare Improvement
Scotland for more than 10 years
Patient voice type 2
Decision maker
European Medicines Agency committees:
• Pharmacovigilance Risk Assessment Committee – one patient member
and one alternate
• Committee for Orphan Medicinal Products – three patient members
(including the co-chair)
• Committee for Advanced Therapies – two patient members and two
alternates
• Paediatric Committee – three patient members and three alternates
• Committee for Medicinal Products for Human Use (CHMP) – one patient
observer (new this year)
The membership structure of all of these committees are the result of
primary legislation at the European level.
Patient voice type 2
Decision maker
Patients are a key stakeholder in healthcare. They should play a role
in designing decision making processes.
Developing the system in isolation disenfranchises the patient
community and is likely to result in a poorer design.
Patients just like other stakeholders will have experience of these
programmes and how their voice has been dealt with in the past. This
should be made use of.
This is how we change how patient voice contributes to HTA decisions!
Patient voice type 3
Policy maker
The most important patient voice in the whole process is that of the
individual making a choice to take a medicine.
Where possible, patients should be empowered to make an informed
choice as to whether to take a medicine, as part of a shared decision
with their clinician.
Patient voice type 4
The individual
Patient voice:
• as information providers
• as decision makers
• as policy makers
• as individuals
Conclusion
At least four types of patient
voice: ALL must play a role
You can download a copy of our Patient Charters on access to
rare disease medicines in England here:
www.geneticalliance.org.uk/hstcharter.htm
www.geneticalliance.org.uk/nhsenglandcharter.htm
Acknowledgements
• All those that participated in the workshops
• All colleagues that have worked together with us
• NICE and NHS England
Links and acknowledgements
Thank you!
Nick Meade
Director of Policy
+44 (0) 207 704 3141
nick@geneticalliance.org.uk
Registered charity numbers: 1114195 and SC039299
Registered company number: 05772999

More Related Content

What's hot

Jornadas #PatientInHTA · François Houyez
Jornadas #PatientInHTA · François Houyez Jornadas #PatientInHTA · François Houyez
Jornadas #PatientInHTA · François Houyez
Instituto Aragonés de Ciencias de la Salud - IACS
 
Jornadas #PatientInHTA · Valentina Strammiello
Jornadas #PatientInHTA · Valentina StrammielloJornadas #PatientInHTA · Valentina Strammiello
Jornadas #PatientInHTA · Valentina Strammiello
Instituto Aragonés de Ciencias de la Salud - IACS
 
Introduction to the breakout sessions & case studies presentations
Introduction to the breakout sessions & case studies presentationsIntroduction to the breakout sessions & case studies presentations
Introduction to the breakout sessions & case studies presentations
EUPATI
 
Jornadas #PatientInHTA · Nicholas Brooke
Jornadas #PatientInHTA · Nicholas BrookeJornadas #PatientInHTA · Nicholas Brooke
Jornadas #PatientInHTA · Nicholas Brooke
Instituto Aragonés de Ciencias de la Salud - IACS
 
Jornadas #PatientInHTA · Isabel Amo
Jornadas #PatientInHTA · Isabel AmoJornadas #PatientInHTA · Isabel Amo
Jornadas #PatientInHTA · Isabel Amo
Instituto Aragonés de Ciencias de la Salud - IACS
 
Jornadas #PatientInHTA · Jesús González
Jornadas #PatientInHTA · Jesús GonzálezJornadas #PatientInHTA · Jesús González
Jornadas #PatientInHTA · Jesús González
Instituto Aragonés de Ciencias de la Salud - IACS
 
Jornadas #PatientInHTA · Ana Toledo
Jornadas #PatientInHTA · Ana ToledoJornadas #PatientInHTA · Ana Toledo
Jornadas #PatientInHTA · Ana Toledo
Instituto Aragonés de Ciencias de la Salud - IACS
 
Jornadas #PatientInHTA · Yolanda Triñanes
Jornadas #PatientInHTA · Yolanda TriñanesJornadas #PatientInHTA · Yolanda Triñanes
Jornadas #PatientInHTA · Yolanda Triñanes
Instituto Aragonés de Ciencias de la Salud - IACS
 
Changes in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldChanges in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical world
jangeissler
 
Jornadas #PatientInHTA · Tammy Clifford
Jornadas #PatientInHTA · Tammy CliffordJornadas #PatientInHTA · Tammy Clifford
Jornadas #PatientInHTA · Tammy Clifford
Instituto Aragonés de Ciencias de la Salud - IACS
 
Similarities and differences between Rare Cancers and Rare Diseases
Similarities and differences between Rare Cancers and Rare DiseasesSimilarities and differences between Rare Cancers and Rare Diseases
Similarities and differences between Rare Cancers and Rare Diseases
jangeissler
 
0105 Tamas Bereczky - Healthcare ecosystem
0105 Tamas Bereczky - Healthcare ecosystem0105 Tamas Bereczky - Healthcare ecosystem
0105 Tamas Bereczky - Healthcare ecosystem
Workgroup of European Cancer Patient Advocacy Networks
 
Jornadas #PatientInHTA · Iñaki Imaz
Jornadas #PatientInHTA · Iñaki ImazJornadas #PatientInHTA · Iñaki Imaz
Jornadas #PatientInHTA · Iñaki Imaz
Instituto Aragonés de Ciencias de la Salud - IACS
 
0201a pemberton w how to create evidence for advocacy impact 1.1
0201a pemberton w   how to create evidence for advocacy impact 1.10201a pemberton w   how to create evidence for advocacy impact 1.1
0201a pemberton w how to create evidence for advocacy impact 1.1
Workgroup of European Cancer Patient Advocacy Networks
 
0401 2 Ananda Plate - Patient Preferences
0401 2 Ananda Plate - Patient Preferences0401 2 Ananda Plate - Patient Preferences
0401 2 Ananda Plate - Patient Preferences
Workgroup of European Cancer Patient Advocacy Networks
 
0401 1 Denis Costello - Patient Generated Data
0401 1 Denis Costello - Patient Generated Data0401 1 Denis Costello - Patient Generated Data
0401 1 Denis Costello - Patient Generated Data
Workgroup of European Cancer Patient Advocacy Networks
 
0304 Zack Pemberton - Influencing reimbursement decisions as a patient advocate
0304 Zack Pemberton - Influencing reimbursement decisions as a patient advocate0304 Zack Pemberton - Influencing reimbursement decisions as a patient advocate
0304 Zack Pemberton - Influencing reimbursement decisions as a patient advocate
Workgroup of European Cancer Patient Advocacy Networks
 
Paula Kim
Paula KimPaula Kim
Patient engagement in clinical trials
Patient engagement in clinical trials Patient engagement in clinical trials
Patient engagement in clinical trials
Martin Kelly
 
Juliet Moritz premiere research crdn summit 2017
Juliet Moritz premiere research crdn summit 2017Juliet Moritz premiere research crdn summit 2017
Juliet Moritz premiere research crdn summit 2017
CamRARE Disease Network
 

What's hot (20)

Jornadas #PatientInHTA · François Houyez
Jornadas #PatientInHTA · François Houyez Jornadas #PatientInHTA · François Houyez
Jornadas #PatientInHTA · François Houyez
 
Jornadas #PatientInHTA · Valentina Strammiello
Jornadas #PatientInHTA · Valentina StrammielloJornadas #PatientInHTA · Valentina Strammiello
Jornadas #PatientInHTA · Valentina Strammiello
 
Introduction to the breakout sessions & case studies presentations
Introduction to the breakout sessions & case studies presentationsIntroduction to the breakout sessions & case studies presentations
Introduction to the breakout sessions & case studies presentations
 
Jornadas #PatientInHTA · Nicholas Brooke
Jornadas #PatientInHTA · Nicholas BrookeJornadas #PatientInHTA · Nicholas Brooke
Jornadas #PatientInHTA · Nicholas Brooke
 
Jornadas #PatientInHTA · Isabel Amo
Jornadas #PatientInHTA · Isabel AmoJornadas #PatientInHTA · Isabel Amo
Jornadas #PatientInHTA · Isabel Amo
 
Jornadas #PatientInHTA · Jesús González
Jornadas #PatientInHTA · Jesús GonzálezJornadas #PatientInHTA · Jesús González
Jornadas #PatientInHTA · Jesús González
 
Jornadas #PatientInHTA · Ana Toledo
Jornadas #PatientInHTA · Ana ToledoJornadas #PatientInHTA · Ana Toledo
Jornadas #PatientInHTA · Ana Toledo
 
Jornadas #PatientInHTA · Yolanda Triñanes
Jornadas #PatientInHTA · Yolanda TriñanesJornadas #PatientInHTA · Yolanda Triñanes
Jornadas #PatientInHTA · Yolanda Triñanes
 
Changes in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldChanges in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical world
 
Jornadas #PatientInHTA · Tammy Clifford
Jornadas #PatientInHTA · Tammy CliffordJornadas #PatientInHTA · Tammy Clifford
Jornadas #PatientInHTA · Tammy Clifford
 
Similarities and differences between Rare Cancers and Rare Diseases
Similarities and differences between Rare Cancers and Rare DiseasesSimilarities and differences between Rare Cancers and Rare Diseases
Similarities and differences between Rare Cancers and Rare Diseases
 
0105 Tamas Bereczky - Healthcare ecosystem
0105 Tamas Bereczky - Healthcare ecosystem0105 Tamas Bereczky - Healthcare ecosystem
0105 Tamas Bereczky - Healthcare ecosystem
 
Jornadas #PatientInHTA · Iñaki Imaz
Jornadas #PatientInHTA · Iñaki ImazJornadas #PatientInHTA · Iñaki Imaz
Jornadas #PatientInHTA · Iñaki Imaz
 
0201a pemberton w how to create evidence for advocacy impact 1.1
0201a pemberton w   how to create evidence for advocacy impact 1.10201a pemberton w   how to create evidence for advocacy impact 1.1
0201a pemberton w how to create evidence for advocacy impact 1.1
 
0401 2 Ananda Plate - Patient Preferences
0401 2 Ananda Plate - Patient Preferences0401 2 Ananda Plate - Patient Preferences
0401 2 Ananda Plate - Patient Preferences
 
0401 1 Denis Costello - Patient Generated Data
0401 1 Denis Costello - Patient Generated Data0401 1 Denis Costello - Patient Generated Data
0401 1 Denis Costello - Patient Generated Data
 
0304 Zack Pemberton - Influencing reimbursement decisions as a patient advocate
0304 Zack Pemberton - Influencing reimbursement decisions as a patient advocate0304 Zack Pemberton - Influencing reimbursement decisions as a patient advocate
0304 Zack Pemberton - Influencing reimbursement decisions as a patient advocate
 
Paula Kim
Paula KimPaula Kim
Paula Kim
 
Patient engagement in clinical trials
Patient engagement in clinical trials Patient engagement in clinical trials
Patient engagement in clinical trials
 
Juliet Moritz premiere research crdn summit 2017
Juliet Moritz premiere research crdn summit 2017Juliet Moritz premiere research crdn summit 2017
Juliet Moritz premiere research crdn summit 2017
 

Viewers also liked

Health Technology Assessment
Health Technology AssessmentHealth Technology Assessment
Health Technology Assessment
EUPATI
 
Informed consent for incapacitated patients and in emergency situations.
Informed consent for incapacitated patients and in emergency situations.Informed consent for incapacitated patients and in emergency situations.
Informed consent for incapacitated patients and in emergency situations.
EUPATI
 
Protection of subjects and informed consent - the clinical trials regulation ...
Protection of subjects and informed consent - the clinical trials regulation ...Protection of subjects and informed consent - the clinical trials regulation ...
Protection of subjects and informed consent - the clinical trials regulation ...
EUPATI
 
Communication & social media
Communication & social media Communication & social media
Communication & social media
EUPATI
 
EUPATI 2013 Conference: Building Knowledge & Competences for Patients’ Involv...
EUPATI 2013 Conference: Building Knowledge & Competences for Patients’ Involv...EUPATI 2013 Conference: Building Knowledge & Competences for Patients’ Involv...
EUPATI 2013 Conference: Building Knowledge & Competences for Patients’ Involv...
EUPATI
 
Patient involvement prior to regulatory Scientific Advice
Patient involvement prior to regulatory Scientific AdvicePatient involvement prior to regulatory Scientific Advice
Patient involvement prior to regulatory Scientific Advice
EUPATI
 
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...
EUPATI
 
EUPATI 2013 Conference: Welcome and Introduction
EUPATI 2013 Conference: Welcome and IntroductionEUPATI 2013 Conference: Welcome and Introduction
EUPATI 2013 Conference: Welcome and Introduction
EUPATI
 
Delivering Professional IT Services; Mind the gap of Cultural Risks
Delivering Professional IT Services; Mind the gap of Cultural RisksDelivering Professional IT Services; Mind the gap of Cultural Risks
Delivering Professional IT Services; Mind the gap of Cultural Risks
Dr Harris Apostolopoulos EMBA, PfMP, PgMP, PMP, IPMO-E
 
Present progressivenvo
Present progressivenvoPresent progressivenvo
Present progressivenvo
Jessi Custodio
 
Present progressiveana
Present progressiveanaPresent progressiveana
Present progressiveana
Jessi Custodio
 
EUPATI 2013 Conference: Patient involvement in medicines R&D: Bringing to li...
EUPATI 2013 Conference: Patient involvement in medicines R&D: Bringing to li...EUPATI 2013 Conference: Patient involvement in medicines R&D: Bringing to li...
EUPATI 2013 Conference: Patient involvement in medicines R&D: Bringing to li...
EUPATI
 
G4 report from breakout group 4
G4 report from breakout group 4G4 report from breakout group 4
G4 report from breakout group 4
EUPATI
 
Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013
Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013
Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013
EUPATI
 
Mini-Course Starter Kits
Mini-Course Starter KitsMini-Course Starter Kits
Mini-Course Starter Kits
EUPATI
 
Blood basics in Dentistry
Blood basics in DentistryBlood basics in Dentistry
Blood basics in Dentistry
Abhishek Gakhar
 
Introduction to the break out sessions & case studies presentations
Introduction to the break out sessions & case studies presentationsIntroduction to the break out sessions & case studies presentations
Introduction to the break out sessions & case studies presentations
EUPATI
 
Occlusion in Periodontics
Occlusion in PeriodonticsOcclusion in Periodontics
Occlusion in Periodontics
Abhishek Gakhar
 
Periodontal Ligament
Periodontal LigamentPeriodontal Ligament
Periodontal Ligament
Abhishek Gakhar
 

Viewers also liked (19)

Health Technology Assessment
Health Technology AssessmentHealth Technology Assessment
Health Technology Assessment
 
Informed consent for incapacitated patients and in emergency situations.
Informed consent for incapacitated patients and in emergency situations.Informed consent for incapacitated patients and in emergency situations.
Informed consent for incapacitated patients and in emergency situations.
 
Protection of subjects and informed consent - the clinical trials regulation ...
Protection of subjects and informed consent - the clinical trials regulation ...Protection of subjects and informed consent - the clinical trials regulation ...
Protection of subjects and informed consent - the clinical trials regulation ...
 
Communication & social media
Communication & social media Communication & social media
Communication & social media
 
EUPATI 2013 Conference: Building Knowledge & Competences for Patients’ Involv...
EUPATI 2013 Conference: Building Knowledge & Competences for Patients’ Involv...EUPATI 2013 Conference: Building Knowledge & Competences for Patients’ Involv...
EUPATI 2013 Conference: Building Knowledge & Competences for Patients’ Involv...
 
Patient involvement prior to regulatory Scientific Advice
Patient involvement prior to regulatory Scientific AdvicePatient involvement prior to regulatory Scientific Advice
Patient involvement prior to regulatory Scientific Advice
 
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...
 
EUPATI 2013 Conference: Welcome and Introduction
EUPATI 2013 Conference: Welcome and IntroductionEUPATI 2013 Conference: Welcome and Introduction
EUPATI 2013 Conference: Welcome and Introduction
 
Delivering Professional IT Services; Mind the gap of Cultural Risks
Delivering Professional IT Services; Mind the gap of Cultural RisksDelivering Professional IT Services; Mind the gap of Cultural Risks
Delivering Professional IT Services; Mind the gap of Cultural Risks
 
Present progressivenvo
Present progressivenvoPresent progressivenvo
Present progressivenvo
 
Present progressiveana
Present progressiveanaPresent progressiveana
Present progressiveana
 
EUPATI 2013 Conference: Patient involvement in medicines R&D: Bringing to li...
EUPATI 2013 Conference: Patient involvement in medicines R&D: Bringing to li...EUPATI 2013 Conference: Patient involvement in medicines R&D: Bringing to li...
EUPATI 2013 Conference: Patient involvement in medicines R&D: Bringing to li...
 
G4 report from breakout group 4
G4 report from breakout group 4G4 report from breakout group 4
G4 report from breakout group 4
 
Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013
Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013
Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013
 
Mini-Course Starter Kits
Mini-Course Starter KitsMini-Course Starter Kits
Mini-Course Starter Kits
 
Blood basics in Dentistry
Blood basics in DentistryBlood basics in Dentistry
Blood basics in Dentistry
 
Introduction to the break out sessions & case studies presentations
Introduction to the break out sessions & case studies presentationsIntroduction to the break out sessions & case studies presentations
Introduction to the break out sessions & case studies presentations
 
Occlusion in Periodontics
Occlusion in PeriodonticsOcclusion in Periodontics
Occlusion in Periodontics
 
Periodontal Ligament
Periodontal LigamentPeriodontal Ligament
Periodontal Ligament
 

Similar to Patients’ voice in access decisions

PowerPoint Presentation +.ppt
PowerPoint Presentation +.pptPowerPoint Presentation +.ppt
PowerPoint Presentation +.ppt
Shaan73
 
Afternoon Session A Consultation on Patented Medicine Prices Review Board & B...
Afternoon Session A Consultation on Patented Medicine Prices Review Board & B...Afternoon Session A Consultation on Patented Medicine Prices Review Board & B...
Afternoon Session A Consultation on Patented Medicine Prices Review Board & B...
Canadian Organization for Rare Disorders
 
Right care sdm_launch_presentation_sept_2011
Right care sdm_launch_presentation_sept_2011Right care sdm_launch_presentation_sept_2011
Right care sdm_launch_presentation_sept_2011
rightcare
 
From disease-centered to patient-centered communication in breast cancer
From disease-centered to patient-centered communication in breast cancerFrom disease-centered to patient-centered communication in breast cancer
From disease-centered to patient-centered communication in breast cancer
Kathi Apostolidis
 
CP_1_introduction_to_community_pharmacy_Ms_Asma.pptx
CP_1_introduction_to_community_pharmacy_Ms_Asma.pptxCP_1_introduction_to_community_pharmacy_Ms_Asma.pptx
CP_1_introduction_to_community_pharmacy_Ms_Asma.pptx
ValentinoDhiyu1
 
Rare Solid Cancers: An Introduction - Slide 5 - J. Geissler - Patient advocac...
Rare Solid Cancers: An Introduction - Slide 5 - J. Geissler - Patient advocac...Rare Solid Cancers: An Introduction - Slide 5 - J. Geissler - Patient advocac...
Rare Solid Cancers: An Introduction - Slide 5 - J. Geissler - Patient advocac...
European School of Oncology
 
What do people think about medicines research and development? (Starling, EUP...
What do people think about medicines research and development? (Starling, EUP...What do people think about medicines research and development? (Starling, EUP...
What do people think about medicines research and development? (Starling, EUP...
Nowgen
 
Role of the Natural Medicine Physician Within the New Health Care Paradigm - ...
Role of the Natural Medicine Physician Within the New Health Care Paradigm - ...Role of the Natural Medicine Physician Within the New Health Care Paradigm - ...
Role of the Natural Medicine Physician Within the New Health Care Paradigm - ...
National University of Health Sciences
 
DIA Global Forum: Are Clinical Trials Ready to Embrace the IoE?
DIA Global Forum: Are Clinical Trials Ready to Embrace the IoE?DIA Global Forum: Are Clinical Trials Ready to Embrace the IoE?
DIA Global Forum: Are Clinical Trials Ready to Embrace the IoE?
Jackie Brusch
 
Pharmacist in public health npw ppt
Pharmacist in public health   npw pptPharmacist in public health   npw ppt
Pharmacist in public health npw ppt
Sai Datri Arige
 
The American prescription opioid crisis
The American prescription opioid crisisThe American prescription opioid crisis
The American prescription opioid crisis
scanFOAM
 
Population Health
Population HealthPopulation Health
Population Health
PYA, P.C.
 
CSC
CSCCSC
Elevating-the-Patient-Voice
Elevating-the-Patient-VoiceElevating-the-Patient-Voice
Elevating-the-Patient-Voice
Bev Soult
 
Polypharmacy - What next? (Planning for Wessex) Workshop - Clare Howard's pre...
Polypharmacy - What next? (Planning for Wessex) Workshop - Clare Howard's pre...Polypharmacy - What next? (Planning for Wessex) Workshop - Clare Howard's pre...
Polypharmacy - What next? (Planning for Wessex) Workshop - Clare Howard's pre...
Health Innovation Wessex
 
International nurses day 2019
International nurses day 2019International nurses day 2019
International nurses day 2019
subhasarada1977
 
Sir Muir Gray - CLAHRC East Midlands launch event
Sir Muir Gray - CLAHRC East Midlands launch eventSir Muir Gray - CLAHRC East Midlands launch event
Sir Muir Gray - CLAHRC East Midlands launch event
CLAHRC-NDL
 
EANM patient information on thyroid cancer
EANM patient information on thyroid cancerEANM patient information on thyroid cancer
EANM patient information on thyroid cancer
Marika Porrey
 
Cancer Heart Disease.ppt
Cancer Heart Disease.pptCancer Heart Disease.ppt
Cancer Heart Disease.ppt
PranjalAgrawal64
 
Kyle molina harm reduction midterm project unm crp 275 community change in a ...
Kyle molina harm reduction midterm project unm crp 275 community change in a ...Kyle molina harm reduction midterm project unm crp 275 community change in a ...
Kyle molina harm reduction midterm project unm crp 275 community change in a ...
Dr. J
 

Similar to Patients’ voice in access decisions (20)

PowerPoint Presentation +.ppt
PowerPoint Presentation +.pptPowerPoint Presentation +.ppt
PowerPoint Presentation +.ppt
 
Afternoon Session A Consultation on Patented Medicine Prices Review Board & B...
Afternoon Session A Consultation on Patented Medicine Prices Review Board & B...Afternoon Session A Consultation on Patented Medicine Prices Review Board & B...
Afternoon Session A Consultation on Patented Medicine Prices Review Board & B...
 
Right care sdm_launch_presentation_sept_2011
Right care sdm_launch_presentation_sept_2011Right care sdm_launch_presentation_sept_2011
Right care sdm_launch_presentation_sept_2011
 
From disease-centered to patient-centered communication in breast cancer
From disease-centered to patient-centered communication in breast cancerFrom disease-centered to patient-centered communication in breast cancer
From disease-centered to patient-centered communication in breast cancer
 
CP_1_introduction_to_community_pharmacy_Ms_Asma.pptx
CP_1_introduction_to_community_pharmacy_Ms_Asma.pptxCP_1_introduction_to_community_pharmacy_Ms_Asma.pptx
CP_1_introduction_to_community_pharmacy_Ms_Asma.pptx
 
Rare Solid Cancers: An Introduction - Slide 5 - J. Geissler - Patient advocac...
Rare Solid Cancers: An Introduction - Slide 5 - J. Geissler - Patient advocac...Rare Solid Cancers: An Introduction - Slide 5 - J. Geissler - Patient advocac...
Rare Solid Cancers: An Introduction - Slide 5 - J. Geissler - Patient advocac...
 
What do people think about medicines research and development? (Starling, EUP...
What do people think about medicines research and development? (Starling, EUP...What do people think about medicines research and development? (Starling, EUP...
What do people think about medicines research and development? (Starling, EUP...
 
Role of the Natural Medicine Physician Within the New Health Care Paradigm - ...
Role of the Natural Medicine Physician Within the New Health Care Paradigm - ...Role of the Natural Medicine Physician Within the New Health Care Paradigm - ...
Role of the Natural Medicine Physician Within the New Health Care Paradigm - ...
 
DIA Global Forum: Are Clinical Trials Ready to Embrace the IoE?
DIA Global Forum: Are Clinical Trials Ready to Embrace the IoE?DIA Global Forum: Are Clinical Trials Ready to Embrace the IoE?
DIA Global Forum: Are Clinical Trials Ready to Embrace the IoE?
 
Pharmacist in public health npw ppt
Pharmacist in public health   npw pptPharmacist in public health   npw ppt
Pharmacist in public health npw ppt
 
The American prescription opioid crisis
The American prescription opioid crisisThe American prescription opioid crisis
The American prescription opioid crisis
 
Population Health
Population HealthPopulation Health
Population Health
 
CSC
CSCCSC
CSC
 
Elevating-the-Patient-Voice
Elevating-the-Patient-VoiceElevating-the-Patient-Voice
Elevating-the-Patient-Voice
 
Polypharmacy - What next? (Planning for Wessex) Workshop - Clare Howard's pre...
Polypharmacy - What next? (Planning for Wessex) Workshop - Clare Howard's pre...Polypharmacy - What next? (Planning for Wessex) Workshop - Clare Howard's pre...
Polypharmacy - What next? (Planning for Wessex) Workshop - Clare Howard's pre...
 
International nurses day 2019
International nurses day 2019International nurses day 2019
International nurses day 2019
 
Sir Muir Gray - CLAHRC East Midlands launch event
Sir Muir Gray - CLAHRC East Midlands launch eventSir Muir Gray - CLAHRC East Midlands launch event
Sir Muir Gray - CLAHRC East Midlands launch event
 
EANM patient information on thyroid cancer
EANM patient information on thyroid cancerEANM patient information on thyroid cancer
EANM patient information on thyroid cancer
 
Cancer Heart Disease.ppt
Cancer Heart Disease.pptCancer Heart Disease.ppt
Cancer Heart Disease.ppt
 
Kyle molina harm reduction midterm project unm crp 275 community change in a ...
Kyle molina harm reduction midterm project unm crp 275 community change in a ...Kyle molina harm reduction midterm project unm crp 275 community change in a ...
Kyle molina harm reduction midterm project unm crp 275 community change in a ...
 

More from EUPATI

EUPATI guidances for interaction between Patient organisations and other stak...
EUPATI guidances for interaction between Patient organisations and other stak...EUPATI guidances for interaction between Patient organisations and other stak...
EUPATI guidances for interaction between Patient organisations and other stak...
EUPATI
 
Introduction to the breakout sessions & case studies presentations
Introduction to the breakout sessions & case studies presentationsIntroduction to the breakout sessions & case studies presentations
Introduction to the breakout sessions & case studies presentations
EUPATI
 
EUPATI patient expert training course and its relevance for patient involvement
EUPATI patient expert training course and its relevance for patient involvementEUPATI patient expert training course and its relevance for patient involvement
EUPATI patient expert training course and its relevance for patient involvement
EUPATI
 
Introduction to the workshop and EUPATI update
Introduction to the workshop and EUPATI updateIntroduction to the workshop and EUPATI update
Introduction to the workshop and EUPATI update
EUPATI
 
G3 report from breakout group 3
G3 report from breakout group 3G3 report from breakout group 3
G3 report from breakout group 3
EUPATI
 
G2 report from breakout group 2
G2 report from breakout group 2G2 report from breakout group 2
G2 report from breakout group 2
EUPATI
 
G1 report from breakout group 1
G1 report from breakout group 1G1 report from breakout group 1
G1 report from breakout group 1
EUPATI
 
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...
EUPATI
 
Translating Patient Needs into Robust, Easily Accessible Quality Materials -...
Translating Patient Needs into Robust, Easily Accessible Quality Materials -...Translating Patient Needs into Robust, Easily Accessible Quality Materials -...
Translating Patient Needs into Robust, Easily Accessible Quality Materials -...
EUPATI
 
Researching information needs and beliefs of patients, professionals and the ...
Researching information needs and beliefs of patients, professionals and the ...Researching information needs and beliefs of patients, professionals and the ...
Researching information needs and beliefs of patients, professionals and the ...
EUPATI
 

More from EUPATI (10)

EUPATI guidances for interaction between Patient organisations and other stak...
EUPATI guidances for interaction between Patient organisations and other stak...EUPATI guidances for interaction between Patient organisations and other stak...
EUPATI guidances for interaction between Patient organisations and other stak...
 
Introduction to the breakout sessions & case studies presentations
Introduction to the breakout sessions & case studies presentationsIntroduction to the breakout sessions & case studies presentations
Introduction to the breakout sessions & case studies presentations
 
EUPATI patient expert training course and its relevance for patient involvement
EUPATI patient expert training course and its relevance for patient involvementEUPATI patient expert training course and its relevance for patient involvement
EUPATI patient expert training course and its relevance for patient involvement
 
Introduction to the workshop and EUPATI update
Introduction to the workshop and EUPATI updateIntroduction to the workshop and EUPATI update
Introduction to the workshop and EUPATI update
 
G3 report from breakout group 3
G3 report from breakout group 3G3 report from breakout group 3
G3 report from breakout group 3
 
G2 report from breakout group 2
G2 report from breakout group 2G2 report from breakout group 2
G2 report from breakout group 2
 
G1 report from breakout group 1
G1 report from breakout group 1G1 report from breakout group 1
G1 report from breakout group 1
 
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...
 
Translating Patient Needs into Robust, Easily Accessible Quality Materials -...
Translating Patient Needs into Robust, Easily Accessible Quality Materials -...Translating Patient Needs into Robust, Easily Accessible Quality Materials -...
Translating Patient Needs into Robust, Easily Accessible Quality Materials -...
 
Researching information needs and beliefs of patients, professionals and the ...
Researching information needs and beliefs of patients, professionals and the ...Researching information needs and beliefs of patients, professionals and the ...
Researching information needs and beliefs of patients, professionals and the ...
 

Recently uploaded

Medical oncologic management of Colorectal cancer-1-1.pptx
Medical oncologic management of Colorectal cancer-1-1.pptxMedical oncologic management of Colorectal cancer-1-1.pptx
Medical oncologic management of Colorectal cancer-1-1.pptx
robel26
 
Comfort, Rest, Sleep and Pain.pptx
Comfort, Rest, Sleep  and Pain.pptxComfort, Rest, Sleep  and Pain.pptx
Comfort, Rest, Sleep and Pain.pptx
Nandish Sannaiah
 
Nursing management of patient with peritoneal dialysis
Nursing management of patient with peritoneal dialysisNursing management of patient with peritoneal dialysis
Nursing management of patient with peritoneal dialysis
shivalingatalekar1
 
Recognizing and Managing Bacterial Vaginosis.pptx
Recognizing and Managing Bacterial Vaginosis.pptxRecognizing and Managing Bacterial Vaginosis.pptx
Recognizing and Managing Bacterial Vaginosis.pptx
FFragrant
 
Operation Theatre Nursing -History of Surgery & Anesthesia.pptx
Operation Theatre Nursing -History of Surgery & Anesthesia.pptxOperation Theatre Nursing -History of Surgery & Anesthesia.pptx
Operation Theatre Nursing -History of Surgery & Anesthesia.pptx
RadhaThapaChhetry
 
Why Does Seminal Vesiculitis Causes Jelly-like Sperm.pptx
Why Does Seminal Vesiculitis Causes Jelly-like Sperm.pptxWhy Does Seminal Vesiculitis Causes Jelly-like Sperm.pptx
Why Does Seminal Vesiculitis Causes Jelly-like Sperm.pptx
AmandaChou9
 
THE MANAGEMENT OF PROSTATE CANCER . pptx
THE MANAGEMENT OF PROSTATE CANCER . pptxTHE MANAGEMENT OF PROSTATE CANCER . pptx
THE MANAGEMENT OF PROSTATE CANCER . pptx
Bright Chipili
 
lessonplan JTR.pptx For medical education
lessonplan JTR.pptx For medical educationlessonplan JTR.pptx For medical education
lessonplan JTR.pptx For medical education
DrJALAGAMTHIRUPATHIR
 
Abortion pills for sale in Qatar(+919707208804)Buy Cytotec tablet in Doha
Abortion pills for sale in Qatar(+919707208804)Buy Cytotec tablet in DohaAbortion pills for sale in Qatar(+919707208804)Buy Cytotec tablet in Doha
Abortion pills for sale in Qatar(+919707208804)Buy Cytotec tablet in Doha
maishakhanam230
 
POTENTIAL TARGET DISEASES FOR GENE THERAPY SOURAV.pptx
POTENTIAL TARGET DISEASES FOR GENE THERAPY SOURAV.pptxPOTENTIAL TARGET DISEASES FOR GENE THERAPY SOURAV.pptx
POTENTIAL TARGET DISEASES FOR GENE THERAPY SOURAV.pptx
souravpaul769171
 
TEST BANK For Katzung's Basic and Clinical Pharmacology, 16th Edition By {Tod...
TEST BANK For Katzung's Basic and Clinical Pharmacology, 16th Edition By {Tod...TEST BANK For Katzung's Basic and Clinical Pharmacology, 16th Edition By {Tod...
TEST BANK For Katzung's Basic and Clinical Pharmacology, 16th Edition By {Tod...
rightmanforbloodline
 
Drug Repurposing for Parasitic Diseases.pptx
Drug Repurposing for Parasitic Diseases.pptxDrug Repurposing for Parasitic Diseases.pptx
Drug Repurposing for Parasitic Diseases.pptx
drebrahiim
 
Gestational Trophoblastic Disease( GTD)- Molar pregnancy, Gestational Trophob...
Gestational Trophoblastic Disease( GTD)- Molar pregnancy, Gestational Trophob...Gestational Trophoblastic Disease( GTD)- Molar pregnancy, Gestational Trophob...
Gestational Trophoblastic Disease( GTD)- Molar pregnancy, Gestational Trophob...
Dr.Nishant Janu
 
Dr Charles James de Vis, M.R.C.S., L.S.A. England, Surgeon to the Charters To...
Dr Charles James de Vis, M.R.C.S., L.S.A. England, Surgeon to the Charters To...Dr Charles James de Vis, M.R.C.S., L.S.A. England, Surgeon to the Charters To...
Dr Charles James de Vis, M.R.C.S., L.S.A. England, Surgeon to the Charters To...
semualkaira
 
Exploring Alternatives- Why Laparoscopy Isn't Always Best for Hydrosalpinx.pptx
Exploring Alternatives- Why Laparoscopy Isn't Always Best for Hydrosalpinx.pptxExploring Alternatives- Why Laparoscopy Isn't Always Best for Hydrosalpinx.pptx
Exploring Alternatives- Why Laparoscopy Isn't Always Best for Hydrosalpinx.pptx
FFragrant
 
Perforation.pptx
Perforation.pptxPerforation.pptx
Perforation.pptx
Nandish Sannaiah
 
11_Eclampsia and preeclampsia real.pptxf
11_Eclampsia and preeclampsia real.pptxf11_Eclampsia and preeclampsia real.pptxf
11_Eclampsia and preeclampsia real.pptxf
kkamaraansumana
 
Types of Hypoxia, Hypercapnia, and Cyanosis
Types of Hypoxia, Hypercapnia, and CyanosisTypes of Hypoxia, Hypercapnia, and Cyanosis
Types of Hypoxia, Hypercapnia, and Cyanosis
MedicoseAcademics
 
Journal club presentation JC 28.5.24 edit.pptx
Journal club presentation JC 28.5.24 edit.pptxJournal club presentation JC 28.5.24 edit.pptx
Journal club presentation JC 28.5.24 edit.pptx
AdhyaDubey1
 
2nd week of Human development .embryology
2nd week of Human development .embryology2nd week of Human development .embryology
2nd week of Human development .embryology
Mithilesh Chaurasia
 

Recently uploaded (20)

Medical oncologic management of Colorectal cancer-1-1.pptx
Medical oncologic management of Colorectal cancer-1-1.pptxMedical oncologic management of Colorectal cancer-1-1.pptx
Medical oncologic management of Colorectal cancer-1-1.pptx
 
Comfort, Rest, Sleep and Pain.pptx
Comfort, Rest, Sleep  and Pain.pptxComfort, Rest, Sleep  and Pain.pptx
Comfort, Rest, Sleep and Pain.pptx
 
Nursing management of patient with peritoneal dialysis
Nursing management of patient with peritoneal dialysisNursing management of patient with peritoneal dialysis
Nursing management of patient with peritoneal dialysis
 
Recognizing and Managing Bacterial Vaginosis.pptx
Recognizing and Managing Bacterial Vaginosis.pptxRecognizing and Managing Bacterial Vaginosis.pptx
Recognizing and Managing Bacterial Vaginosis.pptx
 
Operation Theatre Nursing -History of Surgery & Anesthesia.pptx
Operation Theatre Nursing -History of Surgery & Anesthesia.pptxOperation Theatre Nursing -History of Surgery & Anesthesia.pptx
Operation Theatre Nursing -History of Surgery & Anesthesia.pptx
 
Why Does Seminal Vesiculitis Causes Jelly-like Sperm.pptx
Why Does Seminal Vesiculitis Causes Jelly-like Sperm.pptxWhy Does Seminal Vesiculitis Causes Jelly-like Sperm.pptx
Why Does Seminal Vesiculitis Causes Jelly-like Sperm.pptx
 
THE MANAGEMENT OF PROSTATE CANCER . pptx
THE MANAGEMENT OF PROSTATE CANCER . pptxTHE MANAGEMENT OF PROSTATE CANCER . pptx
THE MANAGEMENT OF PROSTATE CANCER . pptx
 
lessonplan JTR.pptx For medical education
lessonplan JTR.pptx For medical educationlessonplan JTR.pptx For medical education
lessonplan JTR.pptx For medical education
 
Abortion pills for sale in Qatar(+919707208804)Buy Cytotec tablet in Doha
Abortion pills for sale in Qatar(+919707208804)Buy Cytotec tablet in DohaAbortion pills for sale in Qatar(+919707208804)Buy Cytotec tablet in Doha
Abortion pills for sale in Qatar(+919707208804)Buy Cytotec tablet in Doha
 
POTENTIAL TARGET DISEASES FOR GENE THERAPY SOURAV.pptx
POTENTIAL TARGET DISEASES FOR GENE THERAPY SOURAV.pptxPOTENTIAL TARGET DISEASES FOR GENE THERAPY SOURAV.pptx
POTENTIAL TARGET DISEASES FOR GENE THERAPY SOURAV.pptx
 
TEST BANK For Katzung's Basic and Clinical Pharmacology, 16th Edition By {Tod...
TEST BANK For Katzung's Basic and Clinical Pharmacology, 16th Edition By {Tod...TEST BANK For Katzung's Basic and Clinical Pharmacology, 16th Edition By {Tod...
TEST BANK For Katzung's Basic and Clinical Pharmacology, 16th Edition By {Tod...
 
Drug Repurposing for Parasitic Diseases.pptx
Drug Repurposing for Parasitic Diseases.pptxDrug Repurposing for Parasitic Diseases.pptx
Drug Repurposing for Parasitic Diseases.pptx
 
Gestational Trophoblastic Disease( GTD)- Molar pregnancy, Gestational Trophob...
Gestational Trophoblastic Disease( GTD)- Molar pregnancy, Gestational Trophob...Gestational Trophoblastic Disease( GTD)- Molar pregnancy, Gestational Trophob...
Gestational Trophoblastic Disease( GTD)- Molar pregnancy, Gestational Trophob...
 
Dr Charles James de Vis, M.R.C.S., L.S.A. England, Surgeon to the Charters To...
Dr Charles James de Vis, M.R.C.S., L.S.A. England, Surgeon to the Charters To...Dr Charles James de Vis, M.R.C.S., L.S.A. England, Surgeon to the Charters To...
Dr Charles James de Vis, M.R.C.S., L.S.A. England, Surgeon to the Charters To...
 
Exploring Alternatives- Why Laparoscopy Isn't Always Best for Hydrosalpinx.pptx
Exploring Alternatives- Why Laparoscopy Isn't Always Best for Hydrosalpinx.pptxExploring Alternatives- Why Laparoscopy Isn't Always Best for Hydrosalpinx.pptx
Exploring Alternatives- Why Laparoscopy Isn't Always Best for Hydrosalpinx.pptx
 
Perforation.pptx
Perforation.pptxPerforation.pptx
Perforation.pptx
 
11_Eclampsia and preeclampsia real.pptxf
11_Eclampsia and preeclampsia real.pptxf11_Eclampsia and preeclampsia real.pptxf
11_Eclampsia and preeclampsia real.pptxf
 
Types of Hypoxia, Hypercapnia, and Cyanosis
Types of Hypoxia, Hypercapnia, and CyanosisTypes of Hypoxia, Hypercapnia, and Cyanosis
Types of Hypoxia, Hypercapnia, and Cyanosis
 
Journal club presentation JC 28.5.24 edit.pptx
Journal club presentation JC 28.5.24 edit.pptxJournal club presentation JC 28.5.24 edit.pptx
Journal club presentation JC 28.5.24 edit.pptx
 
2nd week of Human development .embryology
2nd week of Human development .embryology2nd week of Human development .embryology
2nd week of Human development .embryology
 

Patients’ voice in access decisions

  • 1. Patients’ voice in access decisions A discussion of the roles patients can play Nick Meade Director of Policy Genetic Alliance UK
  • 2. Genetic Alliance UK is the national charity working to improve the lives of patients and families affected by all types of genetic conditions. We are an alliance of over 180 patient organisations. Our aim is to ensure that high quality services, information and support are provided to all who need them. We actively support research and innovation across the field of genetic medicine. Who are we?
  • 3. • Patient voice as information providers • Patient voice in decision making • Patient voice in policy development • Patient voice as an individual Patients’ voice in access decisions A discussion of the roles patients can play
  • 4. “Health technology assessment is the systematic evaluation of the properties and effects of a health technology, addressing the direct and intended effects of this technology, as well as its indirect and unintended consequences, and aimed mainly at informing decision making regarding health technologies.” World Health Organisation Raw material: information Patient voice type 1 Information providers
  • 5. Some types of information required by HTA bodies: •Population size? How many people are affected? How many people need / want the intervention? •What is the impact of the condition? Burden of illness? •How does the disease progress? At what stage should the treatment be given? •What are the adverse events associated with the treatment? What is their impact? •How will the treatment be delivered within the health service? •How effective is the medicine? Is it uniformly effective? Does it work better in certain circumstances? •How much does it cost? What is the value of the improvements it makes? Are these questions valid? Can we answer them in the case of the treatment under discussion? Patient voice type 1 Information providers
  • 6. Example from: The Society for Mucopolysaccharide Diseases (the MPS Society) is the only UK charity supporting individuals and families affected by MPS, Fabry and related diseases. Response to scoping for NICE’s Highly Specialised Technology evaluation of Elosulfase alfa for treating mucopolysaccharidosis type 4A Patient voice type 1 Information providers
  • 7. What is the population size? NICE’s DRAFT Scope for Elosulfase alfa for treating mucopolysaccharidosis type 4A “The exact prevalence of mucopolysaccharidosis type IVA is not known. It has been estimated to affect approximately 1 in 250,000 people in the UK, with 1 new diagnosis per 220,000 live births. This equates to about 200 people living with mucopolysaccharidosis type IVA, and approximately 3 new diagnoses per year, in England.” MPS Society’s response: “The MPS Society has had an MPSIVA registry since 1984 and has collaborated with clinical sites to ensure accuracy and completeness. 94 people living with a biochemical diagnosis in England are on the MPSIVA registry and we do not believe any are missing.” Patient voice type 1 Information providers
  • 8. What outcomes should be considered? NICE’s DRAFT Scope for Elosulfase alfa for treating mucopolysaccharidosis type 4A “The outcome measures to be considered include: MPS Society’s response: “Please consider: But is it easy for patients to play this vital role? Patient voice type 1 Information providers • mobility • respiratory and cardiac function • growth and development • vision and hearing • sleep apnoea • mortality • adverse effects of treatment • health-related quality of life (for patients and carers).” • fatigue • pain • endurance.”
  • 9. Patients are a key stakeholder in healthcare. They should play a role in decision making. Patients and patient groups understand the potential beneficiaries point of view • Is the patient submission being considered appropriately? • Are all potential benefits from this medicine being valued equally? • Just how valuable is a shift from daily treatments to weekly? Patient participation in marketing authorisation decision making has changed the culture of EMA scientific committees. • At least one trained disinterested patient should be part of the decision making panel. Patient voice type 2 Decision maker
  • 10. NICE’s HST Evaluation Committee has: 3 lay members (including someone with knowledge / experience of ethical issues) • Professional ethicist • Member of public • Patient representative (conflicted for one of the products!) Scottish Medicines Consortium 2 public partners • One of whom has been public partner for Healthcare Improvement Scotland for more than 10 years Patient voice type 2 Decision maker
  • 11. European Medicines Agency committees: • Pharmacovigilance Risk Assessment Committee – one patient member and one alternate • Committee for Orphan Medicinal Products – three patient members (including the co-chair) • Committee for Advanced Therapies – two patient members and two alternates • Paediatric Committee – three patient members and three alternates • Committee for Medicinal Products for Human Use (CHMP) – one patient observer (new this year) The membership structure of all of these committees are the result of primary legislation at the European level. Patient voice type 2 Decision maker
  • 12. Patients are a key stakeholder in healthcare. They should play a role in designing decision making processes. Developing the system in isolation disenfranchises the patient community and is likely to result in a poorer design. Patients just like other stakeholders will have experience of these programmes and how their voice has been dealt with in the past. This should be made use of. This is how we change how patient voice contributes to HTA decisions! Patient voice type 3 Policy maker
  • 13. The most important patient voice in the whole process is that of the individual making a choice to take a medicine. Where possible, patients should be empowered to make an informed choice as to whether to take a medicine, as part of a shared decision with their clinician. Patient voice type 4 The individual
  • 14. Patient voice: • as information providers • as decision makers • as policy makers • as individuals Conclusion At least four types of patient voice: ALL must play a role
  • 15. You can download a copy of our Patient Charters on access to rare disease medicines in England here: www.geneticalliance.org.uk/hstcharter.htm www.geneticalliance.org.uk/nhsenglandcharter.htm Acknowledgements • All those that participated in the workshops • All colleagues that have worked together with us • NICE and NHS England Links and acknowledgements
  • 16. Thank you! Nick Meade Director of Policy +44 (0) 207 704 3141 nick@geneticalliance.org.uk Registered charity numbers: 1114195 and SC039299 Registered company number: 05772999